19 February 2021>: Original Paper
Short- and Long-Term Outcomes of Different Reperfusion Sequences in Liver Transplantation
Ann-Kathrin Eichelmann 1BCEF** , Thomas Vogel 1ABE* , Ann-Kathrin Fuchs 1BC , Philipp Houben 1DE , Shadi Katou 1BDF , Felix Becker 1CD , Hartmut H. Schmidt 2AD , Christian Wilms 2DF , Andreas Pascher 1BD , Jens G. Brockmann 1ACDEDOI: 10.12659/AOT.926847
Ann Transplant 2021; 26:e926847
Table 4 12-year post-liver transplant morbidity and mortality.
PV | A | SIM | Total | p | |
---|---|---|---|---|---|
Alive after 12 years | 7 (31.8%) | 7 (28%) | 7 (50%) | 21 (35%) | 0.36 |
Overall survival (median, d) | 848 (0–4982) | 1383 (68–4507) | 3432 (1–4883) | 1733 (0–4982) | 0.16 |
Mean (d) | 1745±2022 | 2142±1732 | 2955±1732 | 2166±1886 | |
Years | 4.8 | 5.9 | 8.1 | 5.9 | |
Retransplantation | 7 (31.8%) | 3 (13.6%) | 0 | 10 (16.4%) | 0.073 |
>1 retransplantation | 2 (2OLT) | 0 | 0 | ||
Graft survival (median, d) | 180 (0–4623) | 1259 (2–4507) | 3432 (1–4883) | 1186 (0–4883) | 0.003 |
Mean (d) | 1191±1722 | 2015±1771 | 2955±1732 | 1893±1846 | |
Years | 3.3 | 5.5 | 8.1 | 5.2 | |
Development of biliary stricture (yes) | 7 (28%) | 5 (22.7%) | 3 (21.4%) | 15 (24.6%) | 0.27 |
ERCP necessity (yes) | 11 (42.6%) | 9 (40.9%) | 6 (42.9%) | 26 (42.6%) | 0.9 |
Number of ERCP | 8.6 (1–40) | 2.3 (1–8) | 5.5 (1–25) | 5.6 | 0.31 |
Rejection treatment (n=49) | N=196 (31.6%) | N=181 (5.3%) | N=121 (8.3%) | N=498 (16.3%) | 0.07 |
Laboratory data | |||||
3 year | |||||
AST | 53±44 | 109±213 | 25±7 | 74±152 | 0.28 |
ALT | 43±32 | 63±75 | 20±10 | 47±56 | 0.11 |
Bilirubin | 1±1.4 | 2.5±6.9 | 0.5±0.3 | 1.3±4.5 | 0.4 |
10 year | |||||
AST | 33±7 | 22±5 | 48±61 | 34±37 | 0.04 |
ALT | 29±8 | 27±12 | 41±46 | 32±29 | 0.7 |
Bilirubin | 0.8±0.8 | 0.4±0.2 | 0.4±0.2 | 0.5±0.46 | 0.6 |
PV – primary portal venous reperfusion; A – primary arterial reperfusion; SIM – simultaneous reperfusion; d – days; ERCP – endoscopic retrograde cholangiopancreatography; AST – aspartate aminotransferase; ALT – alanine aminotransferase. |